An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

Clinical trial NCT05594147 · COMPLETED

Trial details

NCT number: NCT05594147
Sponsor: Bayer
Status: COMPLETED
Study type: OBSERVATIONAL

Malignant Solid Tumors Coronavirus Disease 2019 (COVID-19)SARS-CoV-2 Infection

Start date: 2022-10-31
Primary completion: 2023-04-21
Enrollment: 4103

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.